At Korean Medical Index (KMI), we are committed to delivering precise, objective, and timely intelligence regarding the South Korean biopharmaceutical and healthcare sectors to a global audience. Our publication adheres to the following core editorial standards:
- Data Integration & AI Curation
Our proprietary pipeline monitors verified corporate disclosures, the Ministry of Food and Drug Safety (MFDS) announcements, and reputable domestic news infrastructure. We utilize cutting-edge large language models (LLMs) to synthesize complex scientific findings and financial milestones into structured, professional business English. - Fact-Checking and Verification
Every automated brief undergoes systematic evaluation to ensure data integrity, with a particular focus on quantitative metrics—such as clinical trial percentages, patient cohort sizes, p-values, and monetary licensing figures. - Corrections and Transparency
We do not mask the integration of technology in our content production; rather, we champion it as a mechanism for institutional-grade speed and coverage. If an error is identified in our automated reporting, KMI immediately updates the record with a formal correction notice at the foot of the respective article.